|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
|
DE102004049479A1
(de)
*
|
2004-10-11 |
2006-04-13 |
Scil Proteins Gmbh |
Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
|
|
EP1925664A1
(en)
|
2006-11-15 |
2008-05-28 |
Scil proteins GmbH |
Artificial binding proteins based on a modified alpha helical region of ubiquitin
|
|
EP1955712A1
(en)
|
2007-02-09 |
2008-08-13 |
Scil proteins GmbH |
Multimeric conjugate
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
PT2328616E
(pt)
|
2008-08-05 |
2015-08-26 |
Novartis Ag |
Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
|
|
CA2746840A1
(en)
|
2008-12-16 |
2010-06-24 |
Novartis Ag |
Yeast display systems
|
|
EP3275900A1
(en)
|
2009-04-27 |
2018-01-31 |
Novartis AG |
Compositions and methods for increasing muscle growth
|
|
CA2759942A1
(en)
|
2009-04-27 |
2010-10-07 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
|
|
WO2011018421A1
(en)
|
2009-08-10 |
2011-02-17 |
Morphosys Ag |
Novel screening strategies for the identification of binders
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
US20120321697A1
(en)
*
|
2009-12-11 |
2012-12-20 |
Gwangju Institute Of Science And Technology |
Bpb-based cargo delivery system
|
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
|
JP5667207B2
(ja)
|
2009-12-14 |
2015-02-12 |
シル プロテインズ ゲーエムベーハーＳｃｉｌ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
リガンドへの結合能を有するヘテロ多量体修飾ユビキチンタンパク質の同定方法
|
|
JP5665110B2
(ja)
*
|
2009-12-18 |
2015-02-04 |
独立行政法人農業生物資源研究所 |
外来ＤＮＡ断片由来の逆方向反復配列を含むＤＮＡ断片の調製方法及びＤＮＡ型ＲＮＡｉライブラリの調製方法
|
|
CA2798390A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
EP3366697B1
(en)
|
2010-08-10 |
2020-12-30 |
Sachdev Sidhu |
Specific active site inhibitors of enzymes or substrate binding partners and methods of producing same
|
|
MY162825A
(en)
|
2010-08-20 |
2017-07-31 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
WO2012171541A1
(en)
|
2011-06-15 |
2012-12-20 |
Scil Proteins Gmbh |
Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
|
|
JP6146821B2
(ja)
*
|
2011-06-15 |
2017-06-14 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
修飾ユビキチンに基づく二量体型結合タンパク質
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
DK2726099T3
(en)
|
2011-07-01 |
2018-11-05 |
Novartis Ag |
Method of treating metabolic disorders
|
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
US20130273029A1
(en)
|
2011-12-05 |
2013-10-17 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
WO2013084147A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
SG11201403416TA
(en)
|
2011-12-21 |
2014-07-30 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
|
US9139863B2
(en)
*
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
|
CN104254541A
(zh)
*
|
2012-03-16 |
2014-12-31 |
弗·哈夫曼-拉罗切有限公司 |
改造的构象稳定蛋白质
|
|
WO2013186329A1
(en)
|
2012-06-13 |
2013-12-19 |
Scil Proteins Gmbh |
Human fusion proteins comprising single chain tnfalpha and targeting domains
|
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
|
WO2014044793A2
(en)
|
2012-09-20 |
2014-03-27 |
Max-Delbrück-Centrum für Molekulare Medizin |
Cd22-binding peptides
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
KR102233664B1
(ko)
|
2012-12-05 |
2021-04-02 |
노파르티스 아게 |
Epo를 표적화하는 항체에 대한 조성물 및 방법
|
|
WO2014094799A1
(en)
|
2012-12-19 |
2014-06-26 |
Scil-Proteins-Gmbh |
Ubiquitin moieties as a means for prolonging serum half-life
|
|
TWI632159B
(zh)
|
2013-02-08 |
2018-08-11 |
諾華公司 |
抗－ｉｌ－１７ａ抗體及其於治療自體免疫及發炎病症之用途
|
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
|
EP2970468B1
(en)
|
2013-03-13 |
2021-07-07 |
Novartis AG |
Notch2 binding molecules for treating respiratory diseases
|
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
DK3253795T3
(da)
|
2015-02-06 |
2019-07-29 |
Navigo Proteins Gmbh |
Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter
|
|
US10858405B2
(en)
|
2015-02-06 |
2020-12-08 |
Navigo Proteins Gmbh |
EGFR binding proteins
|
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
US10808042B2
(en)
|
2015-07-16 |
2020-10-20 |
Navigo Proteins Gmbh |
Immunoglobulin-binding proteins and their use in affinity purification
|
|
WO2017013136A1
(en)
*
|
2015-07-20 |
2017-01-26 |
Scil Proteins Gmbh |
Novel binding proteins based on di-ubiquitin muteins and methods for generation
|
|
JP6881760B2
(ja)
*
|
2015-07-20 |
2021-06-02 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
ジユビキチン変異タンパク質に基づくＨｅｒ２結合タンパク質
|
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
|
CU24533B1
(es)
|
2015-09-09 |
2021-07-02 |
Novartis Ag |
Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
|
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
|
AU2016370813A1
(en)
|
2015-12-18 |
2018-06-28 |
Novartis Ag |
Antibodies targeting CD32b and methods of use thereof
|
|
US11312766B2
(en)
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
|
JP2019526526A
(ja)
|
2016-05-04 |
2019-09-19 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
CN110381988A
(zh)
|
2016-06-15 |
2019-10-25 |
诺华股份有限公司 |
使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
|
|
CN109963864B
(zh)
|
2016-08-11 |
2024-01-02 |
瑞普利金公司 |
用于亲和色谱的碱性稳定性fc结合蛋白
|
|
BR112019012667A2
(pt)
|
2016-12-23 |
2020-02-11 |
Novartis Ag |
Anticorpos do fator xi e métodos de uso
|
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
|
PT3600415T
(pt)
|
2017-03-24 |
2025-11-24 |
Novartis Ag |
Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3645564A1
(en)
|
2017-06-28 |
2020-05-06 |
Novartis AG |
Methods for preventing and treating urinary incontinence
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
EP3706804B1
(en)
|
2017-11-07 |
2022-02-23 |
Navigo Proteins GmbH |
Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
|
|
WO2019102353A1
(en)
|
2017-11-22 |
2019-05-31 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
KR20190135393A
(ko)
*
|
2018-05-28 |
2019-12-06 |
주식회사 원진바이오테크놀로지 |
폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
CN110878127B
(zh)
*
|
2018-09-06 |
2022-06-28 |
浙江柏拉阿图医药科技有限公司 |
长效重组GLP1-Fc-CD47蛋白及其制备和用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AR117343A1
(es)
|
2018-12-18 |
2021-07-28 |
Novartis Ag |
AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
|
|
WO2020127224A1
(en)
*
|
2018-12-18 |
2020-06-25 |
Navigo Proteins Gmbh |
Novel folr1 specific binding proteins for cancer diagnosis and treatment
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3136229A1
(en)
*
|
2019-04-10 |
2020-10-15 |
Navigo Proteins Gmbh |
Novel psma specific binding proteins for cancer diagnosis and treatment
|
|
TWI809286B
(zh)
|
2019-07-05 |
2023-07-21 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
|
US20220332825A1
(en)
|
2019-08-08 |
2022-10-20 |
Ono Pharmaceutical Co., Ltd. |
Bispecific protein
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
|
CN111100905B
(zh)
*
|
2019-12-25 |
2021-04-06 |
浙江安诺优达生物科技有限公司 |
缓冲液及其应用
|
|
CA3166629A1
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
US20250099579A1
(en)
|
2021-04-08 |
2025-03-27 |
Marengo Therapeutics, Inc. |
Multispecific molecules binding to tcr and uses thereof
|
|
WO2023094704A1
(en)
*
|
2021-11-29 |
2023-06-01 |
Navigo Proteins Gmbh |
Specific binding molecules for fibroblast activation protein (fap)
|
|
EP4490172A1
(en)
|
2022-03-11 |
2025-01-15 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
|
EP4522630A1
(en)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
|
EP4584291A1
(en)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
US12100373B2
(en)
|
2022-10-12 |
2024-09-24 |
Pearl Musical Instrument Company |
Snare drum strainer structure
|
|
WO2024256643A1
(en)
*
|
2023-06-15 |
2024-12-19 |
Danmarks Tekniske Universitet |
Novel selection methods for the discovery of polypeptides with specific assembly and aggregation properties
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025242732A1
(en)
|
2024-05-21 |
2025-11-27 |
Institut National de la Santé et de la Recherche Médicale |
Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|